Syntex (u.s.a.) Inc.

Celgene Avilomics Research, Inc.

Kymera Therapeutics, Inc.

Mitobridge, Inc.

Celgene Car LLC

The Salk Institute for Biological Studies

Avila Therapeutics, Inc.

Agennix USA Inc.

Other

Forma Therapeutics, Inc.

Gpc Biotech, Inc.

Cubist Pharmaceuticals, Incorporated

Forma Tm, LLC

Gpc Biotech Ag

Innate Biotherapeutics, LLC

Arthur F Kluge

Russell Colyn Petter

Juswinder Singh

Deqiang Niu

Lixin Qiao

Richland Wayne Tester

Nan Ji

Shomir Ghosh

Hormoz Mazdiyasni

William Frederick Westlin, Iii

Nello Mainolfi

Matthew M Weiss

Yi Zhang

Bharat Lagu

Krishna K Murthi

Arthur M Strosberg

Ronald Mark Evans

Michael Downes

Taisuke Takahashi

Sunil Kumar Panigrahi

Robin D Clark

Joseph M Muchowski

Michael A Patane

Masanori Miura

Ramesh Senaiar

Susanta Samajdar

George A Christie

Chris Oalmann

Nicholas Bockovich

Xiaozhang Zheng

Zhongguo Wang

Siya Ram

Roger Whiting

Chase C Smith

Jianxing Huang

Mark G Bock

Jon H Come

Joseph Noel

Roy R Lobb

John F W Keana

Zhendong Zhu

Stefan H Unger

Roger L Whiting

Thomas J Baiga

Rebecca L Casaubon

Frank Becker

Emi Kanakubo Embler

Weiwei Fan

Mike A Patane

Eric Bell

Takashi Ogiyama

Joachim Vogt

Margaret Biddle

John H Fried

Counde O'Yang

Karl G Untch

Ian T Harrison

Xinyuan Edward Wu

Andreas Schoop

Vivian Berlin

Jean-Claude G Pascal

Gabriel Oscar Reznik

Helen Y Wu

Kollol Pal

James Michael Siedlecki

Hua Miao

Ifat Rubin-Bejerano

Sanjita Sasmal

Pranab Maiti

Adolph P Roszkowski

Stefan Hannus

Jason M Hill

Xinyuan Wu

John James Kane

Igor Ivanov

Jan Eickhoff

Roland Köstler

Anthony L Willis

Tilman Brandstetter

Alexander Backes

Lars Neumann

Kerrin Hansen

Peter Amon

Matthias Borgmann

Krishan Murthi

Dennis J Kertesz

Gustave Bergnes

William Frederick Westlin

Iii William Frederick Westlin

The present invention provides compounds, compositions thereof, and methods of using the same for the targeted degradation of proteins, and the treatment of target protein-mediated disorders.

Protein degraders and uses thereof

The present invention provides compounds, compositions thereof, and methods of using the same.

IRAK degraders and uses thereof

The present invention is related to compounds of structure (I) as heme oxygenase 1 (HMOX 1) inducers. (Formula I) The present invention is also related a method of controlling the activity or the amount, or both the activity and the amount, of heme-oxygenase 1 in a mammalian subject. The definitions of the variables are provided herein.

HMOX1 inducers

The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of poly(ADP-ribose)polymerase (PARP). The definitions of the variables are provided herein.

Poly-ADP ribose polymerase (PARP) inhibitors

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.

CRBN ligands and uses thereof

Tricyclic crbn ligands and uses thereof

Provided herein are compounds and compositions useful in increasing PPAR&#x3b4; activity. The compounds and compositions provided herein are useful for the treatment of PPAR&#x3b4; related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof

The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.

2,4-disubstituted pyrimidines useful as kinase inhibitors

Growing community of inventors

Lincoln, MA, United States of America

Arthur F Kluge